Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
ACC/ABC Merck Research Fellow
- License Information
-
More Information
Article History
Received: 8 August 2022
Accepted: 30 October 2024
First Online: 4 December 2024
Competing interests
: C.D.’s spouse is employed by and holds stock in iRhythm Technologies. J.R.T. has received research support and/or has been a consultant for 3ive Labs, Angitia, AskBio, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimensions, Cardurion, CorHepta, Cytokinetics, Daiichi-Sankyo, EBR Systems, Edgewise Therapeutics, Edwards, Endotronix, Impulse Dynamics, JuvLabs, Kaiser Permanente, Lilly, LivaNova, Medtronic, Myovant, Novartis, PCORI, Pfizer, RECARDIO, ReCor Medical, Regeneron, Reprieve, Stealth, Tectonic, V-Wave, Verily, ViCardia and Windtree Therapeutics. L.H. has no competing interests to disclose.
